The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.

Leqembi was rejected by an EU panel based on safety data, while Biogen pulled its previous Alzheimer’s treatment from the market entirely based on a lack of uptake. Cassava Sciences is working ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer ...

Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Ex ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam ...

a blood-based biomarker/diagnostic to detect Alzheimer's disease. Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the ...

The Tsimané people boast the “healthiest hearts on the planet” and brains that age far more slowly than their Western ...